Visual Abstract

Background: Lysophosphatidic acid (LPA) is a small phospholipid-signaling molecule, which can alter responses to stress in the central nervous system. Objective: We hypothesized that exogenous LPA would increase the size of infarct and reduce microregional O2 supply/consumption balance after cerebral ischemia-reperfusion. Methods: This was tested in isoflurane-anesthetized rats with middle cerebral artery blockade for 1 h and reperfusion for 2 h with or without LPA (1 mg/kg, at 30, 60, and 90 min after reperfusion). Regional cerebral blood flow was determined using a C14-iodoantipyrine autoradiographic technique. Regional small-vessel (20–60 µm in diameter) arterial and venous oxygen saturations were determined microspectrophotometrically. Results: There were no significant hemodynamic or arterial blood gas differences between groups. The control ischemic-reperfused cortex had a similar O2 consumption to the contralateral cortex. However, microregional O2 supply/consumption balance was significantly reduced in the ischemic-reperfused cortex with many areas of low O2 saturation (43 of 80 veins with O2 saturation below 50%). LPA did not significantly alter cerebral blood flow, but it did significantly increase O2 extraction and consumption of the ischemic-reperfused region. It also significantly increased the number of small veins with low O2 saturations in the reperfused region (76 of 80 veins with O2 saturation below 50%). This was associated with a significantly increased cortical infarct size after LPA administration (11.4 ± 0.5% control vs. 16.4 ± 0.6% LPA). Conclusion: This suggests that LPA reduces cell survival and that it is associated with an increase in the number of small microregions with reduced local oxygen balance after cerebral ischemia-reperfusion.

1.
Alexandrov
AV
.
Current and future recanalization strategies for acute ischemic stroke
.
J Intern Med
.
2010
Feb
;
267
(
2
):
209
19
.
[PubMed]
0954-6820
2.
Gomis
M
,
Dávalos
A
.
Recanalization and Reperfusion Therapies of Acute Ischemic Stroke: What have We Learned, What are the Major Research Questions, and Where are We Headed?
Front Neurol
.
2014
Nov
;
5
:
226
.
[PubMed]
1664-2295
3.
Shi
H
,
Liu
KJ
.
Cerebral tissue oxygenation and oxidative brain injury during ischemia and reperfusion
.
Front Biosci
.
2007
Jan
;
12
(
1
):
1318
28
.
[PubMed]
1093-9946
4.
Martín
A
,
Rojas
S
,
Pareto
D
,
Santalucia
T
,
Millán
O
,
Abasolo
I
, et al
Depressed glucose consumption at reperfusion following brain ischemia does not correlate with mitochondrial dysfunction and development of infarction: an in vivo positron emission tomography study
.
Curr Neurovasc Res
.
2009
May
;
6
(
2
):
82
8
.
[PubMed]
1567-2026
5.
Tichauer
KM
,
Elliott
JT
,
Hadway
JA
,
Lee
TY
,
St Lawrence
K
.
Cerebral metabolic rate of oxygen and amplitude-integrated electroencephalography during early reperfusion after hypoxia-ischemia in piglets
.
J Appl Physiol (1985)
.
2009
May
;
106
(
5
):
1506
12
.
[PubMed]
8750-7587
6.
Weiss
HR
,
Grayson
J
,
Liu
X
,
Barsoum
S
,
Shah
H
,
Chi
OZ
.
Cerebral ischemia and reperfusion increases the heterogeneity of local oxygen supply/consumption balance
.
Stroke
.
2013
Sep
;
44
(
9
):
2553
8
.
[PubMed]
0039-2499
7.
Buchweitz-Milton
E
,
Weiss
HR
.
Effect of MCA occlusion on brain O2 supply and consumption determined microspectrophotometrically
.
Am J Physiol
.
1987
Aug
;
253
(
2 Pt 2
):
H454
60
.
[PubMed]
0002-9513
8.
Kaur
H
,
Prakash
A
,
Medhi
B
.
Drug therapy in stroke: from preclinical to clinical studies
.
Pharmacology
.
2013
;
92
(
5-6
):
324
34
.
[PubMed]
0031-7012
9.
Siket
MS
.
Treatment of Acute Ischemic Stroke
.
Emerg Med Clin North Am
.
2016
Nov
;
34
(
4
):
861
82
.
[PubMed]
0733-8627
10.
Weiss
HR
,
Chi
OZ
,
Kiss
GK
,
Liu
X
,
Damito
S
,
Jacinto
E
.
Akt activation improves microregional oxygen supply/consumption balance after cerebral ischemia-reperfusion
.
Brain Res
.
2018
Mar
;
1683
:
48
54
.
[PubMed]
0006-8993
11.
Yung
YC
,
Stoddard
NC
,
Chun
J
.
LPA receptor signaling: pharmacology, physiology, and pathophysiology
.
J Lipid Res
.
2014
Jul
;
55
(
7
):
1192
214
.
[PubMed]
0022-2275
12.
Yung
YC
,
Stoddard
NC
,
Mirendil
H
,
Chun
J
.
Lysophosphatidic Acid signaling in the nervous system
.
Neuron
.
2015
Feb
;
85
(
4
):
669
82
.
[PubMed]
0896-6273
13.
Winter
JN
,
Fox
TE
,
Kester
M
,
Jefferson
LS
,
Kimball
SR
.
Phosphatidic acid mediates activation of mTORC1 through the ERK signaling pathway
.
Am J Physiol Cell Physiol
.
2010
Aug
;
299
(
2
):
C335
44
.
[PubMed]
0363-6143
14.
D’Souza
K
,
Nzirorera
C
,
Cowie
AM
,
Varghese
GP
,
Trivedi
P
,
Eichmann
TO
, et al
Autotaxin-LPA signaling contributes to obesity-induced insulin resistance in muscle and impairs mitochondrial metabolism
.
J Lipid Res
.
2018
Oct
;
59
(
10
):
1805
17
.
[PubMed]
0022-2275
15.
Rancoule
C
,
Attané
C
,
Grès
S
,
Fournel
A
,
Dusaulcy
R
,
Bertrand
C
, et al
Lysophosphatidic acid impairs glucose homeostasis and inhibits insulin secretion in high-fat diet obese mice
.
Diabetologia
.
2013
Jun
;
56
(
6
):
1394
402
.
[PubMed]
0012-186X
16.
Yu
Y
,
Qin
J
,
Liu
M
,
Ruan
Q
,
Li
Y
,
Zhang
Z
.
Role of Rho kinase in lysophosphatidic acid-induced altering of blood-brain barrier permeability
.
Int J Mol Med
.
2014
Mar
;
33
(
3
):
661
9
.
[PubMed]
1107-3756
17.
On
NH
,
Savant
S
,
Toews
M
,
Miller
DW
.
Rapid and reversible enhancement of blood-brain barrier permeability using lysophosphatidic acid
.
J Cereb Blood Flow Metab
.
2013
Dec
;
33
(
12
):
1944
54
.
[PubMed]
0271-678X
18.
Lipsanen
A
,
Jolkkonen
J
.
Experimental approaches to study functional recovery following cerebral ischemia
.
Cell Mol Life Sci
.
2011
Sep
;
68
(
18
):
3007
17
.
[PubMed]
1420-682X
19.
Sommer
CJ
.
Ischemic stroke: experimental models and reality
.
Acta Neuropathol
.
2017
Feb
;
133
(
2
):
245
61
.
[PubMed]
0001-6322
20.
Zhu
NH
,
Weiss
HR
.
Oxy- and carboxyhemoglobin saturation determination in frozen small vessels
.
Am J Physiol
.
1991
Feb
;
260
(
2 Pt 2
):
H626
31
.
[PubMed]
0002-9513
21.
Sinha
AK
,
Neubauer
JA
,
Lipp
JA
,
Weiss
HR
.
Blood O2 saturation determination in frozen tissue
.
Microvasc Res
.
1977
Sep
;
14
(
2
):
133
44
.
[PubMed]
0026-2862
22.
Chi
OZ
,
Barsoum
S
,
Vega-Cotto
NM
,
Jacinto
E
,
Liu
X
,
Mellender
SJ
, et al
Effects of rapamycin on cerebral oxygen supply and consumption during reperfusion after cerebral ischemia
.
Neuroscience
.
2016
Mar
;
316
:
321
7
.
[PubMed]
0306-4522
23.
Dirnagl
U
.
Pathobiology of injury after stroke: the neurovascular unit and beyond
.
Ann N Y Acad Sci
.
2012
Sep
;
1268
(
1
):
21
5
.
[PubMed]
0077-8923
24.
Chi
OZ
,
Hunter
C
,
Liu
X
,
Weiss
HR
.
The effects of isoflurane pretreatment on cerebral blood flow, capillary permeability, and oxygen consumption in focal cerebral ischemia in rats
.
Anesth Analg
.
2010
May
;
110
(
5
):
1412
8
.
[PubMed]
0003-2999
25.
Sakatani
K
,
Murata
Y
,
Fujiwara
N
,
Hoshino
T
,
Nakamura
S
,
Kano
T
, et al
Comparison of blood-oxygen-level-dependent functional magnetic resonance imaging and near-infrared spectroscopy recording during functional brain activation in patients with stroke and brain tumors
.
J Biomed Opt
.
2007
Nov-Dec
;
12
(
6
):
062110
.
[PubMed]
1083-3668
26.
Riaz
A
,
Huang
Y
,
Johansson
S
.
G-Protein-Coupled Lysophosphatidic Acid Receptors and Their Regulation of AKT Signaling
.
Int J Mol Sci
.
2016
Feb
;
17
(
2
):
215
.
[PubMed]
1661-6596
27.
Ruisanchez
É
,
Dancs
P
,
Kerék
M
,
Németh
T
,
Faragó
B
,
Balogh
A
, et al
Lysophosphatidic acid induces vasodilation mediated by LPA1 receptors, phospholipase C, and endothelial nitric oxide synthase
.
FASEB J
.
2014
Feb
;
28
(
2
):
880
90
.
[PubMed]
0892-6638
28.
Chabowski
DS
,
Kadlec
AO
,
Ait-Aissa
K
,
Hockenberry
JC
,
Pearson
PJ
,
Beyer
AM
, et al
Lysophosphatidic acid acts on LPA1 receptor to increase H2 O2 during flow-induced dilation in human adipose arterioles
.
Br J Pharmacol
.
2018
Nov
;
175
(
22
):
4266
80
.
[PubMed]
0007-1188
29.
Dancs
PT
,
Ruisanchez
É
,
Balogh
A
,
Panta
CR
,
Miklós
Z
,
Nüsing
RM
, et al
LPA1 receptor-mediated thromboxane A2 release is responsible for lysophosphatidic acid-induced vascular smooth muscle contraction
.
FASEB J
.
2017
Apr
;
31
(
4
):
1547
55
.
[PubMed]
0892-6638
30.
Staiculescu
MC
,
Ramirez-Perez
FI
,
Castorena-Gonzalez
JA
,
Hong
Z
,
Sun
Z
,
Meininger
GA
, et al
Lysophosphatidic acid induces integrin activation in vascular smooth muscle and alters arteriolar myogenic vasoconstriction
.
Front Physiol
.
2014
Oct
;
5
:
413
.
[PubMed]
1664-042X
31.
Castilla-Ortega
E
,
Escuredo
L
,
Bilbao
A
,
Pedraza
C
,
Orio
L
,
Estivill-Torrús
G
, et al
1-Oleoyl lysophosphatidic acid: a new mediator of emotional behavior in rats
.
PLoS One
.
2014
Jan
;
9
(
1
):
e85348
.
[PubMed]
1932-6203
32.
Yea
K
,
Kim
J
,
Lim
S
,
Park
HS
,
Park
KS
,
Suh
PG
, et al
Lysophosphatidic acid regulates blood glucose by stimulating myotube and adipocyte glucose uptake
.
J Mol Med (Berl)
.
2008
Feb
;
86
(
2
):
211
20
.
[PubMed]
0946-2716
33.
Keller
JN
,
Steiner
MR
,
Mattson
MP
,
Steiner
SM
.
Lysophosphatidic acid decreases glutamate and glucose uptake by astrocytes
.
J Neurochem
.
1996
Dec
;
67
(
6
):
2300
5
.
[PubMed]
0022-3042
34.
Willard
FS
,
Berven
LA
,
Crouch
MF
.
Lysophosphatidic acid activates the 70-kDa S6 kinase via the lipoxygenase pathway
.
Biochem Biophys Res Commun
.
2001
Sep
;
287
(
3
):
607
13
.
[PubMed]
0006-291X
35.
Kam
Y
,
Exton
JH
.
Role of phospholipase D1 in the regulation of mTOR activity by lysophosphatidic acid
.
FASEB J
.
2004
Feb
;
18
(
2
):
311
9
.
[PubMed]
0892-6638
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.